Witryna21 paź 2024 · Immunic ( IMUX) stock is taking a beating on clinical trial data today. The company saw unexpected placebo rates in its study. This has heavy trading dragging … Witryna5 kwi 2024 · Immunic noted that the CALDOSE-1 trial of vidofludimus calcium in moderate-to-severe UC was a phase 2b, multicenter, randomized, double-blind, placebo-controlled, dose-finding study, including a blinded 10-week induction phase and a blinded 50-week maintenance phase. ... The company said it will host a webcast today, April …
Wedbush Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
Witryna7 mar 2024 · Immunic's novel RRMS treatment vidofludimus calcium may offer similar efficacy and better safety than approved MS therapies, new data shows. ... The … Witryna1 paź 2024 · by Patricia Inacio, PhD October 1, 2024. Immunic Therapeutics has enrolled the first patient in a Phase 2 clinical trial testing its oral therapy candidate … curly pop
Solveiga Sujetove – Head of Quality Management – Immunic
Witryna5 kwi 2024 · Immunic will host a webcast today at 8:00 am ET. To participate in the webcast, please register in advance at: ... Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. US IR Contact Rx Communications Group Paula Schwartz +1 917 633 7790 … Witryna5 kwi 2024 · (RTTNews) - Immunic, Inc. (IMUX) Wednesday reported positive data from the maintenance phase of its phase 2b CALDOSE-1 study of lead drug candidate, … Witryna10 maj 2024 · NEW YORK, May 10, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX ), a clinical-stage biopharmaceutical company developing a pipeline of selective … curly poodle cuts